Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis
Sofinnova Partners announced that portfolio company Myricx Bio has agreed to be acquired by Novartis, strengthening the company's oncology pipeline and ADC capabilities.
Myricx Bio | 06/07/2026 | By Akanki
Myricx Bio Secures EUR 90 Million in Series A Financing
Myricx Bio has raised EUR 90 Million (USD 114 Million) in the latest Series A financing round.
Myricx Bio | 08/07/2024 | By Aishwarya | 521
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy